Amlodipine for migraine prophylaxis

Migraine is among the most common neurologic disorders encountered in clini cal practice.(1) In the general US population, the annual incidence has bee n calculated to be approximately 250 per 100 000 with a point prevalence of 10%.(2) Females are affected more than males. A variety of prophylactic an d abortive medications are being used for treatment and several are being s tudied in clinical trials. Calcium-channel blockers are frequently used pro phylactic medications. We report two patients with migraine successfully tr eated with amlodipine (Norvasc, Pfizer, Inc), a slow calcium-channel blocke r. To our knowledge, these are the first reported cases of amlodipine used in migraine prophylaxis.